Classical and alternative nuclear factor-ΚB pathways: A comparison among normal prostate, benign prostate hyperplasia and prostate cancer

Pathology and Oncology Research

Volumn 17, Issue 4, 2011, Pages 873-878

  Cai, Chao ^a   Jiang, Fu Neng ^a   Liang, Yu Xiang ^a   He, Hui Chan ^a   Han, Zhao Dong ^a   Dai, Qi Shan ^a   Qin, Guo Qiang ^a   Chen, Jia Hong ^a   Chen, Xi Bin ^a   Chen, Yan Ru ^a   Zeng, Guo Hua ^a   Zhu, Jian Guo ^b   Zhong, Wei De ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b GUIZHOU PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Immunohistochemistry; Nuclear factor B; Prognosis; Prostate cancer; Real time quantitative RT PCR

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P100; PROTEIN P105; PROTEIN P50; PROTEIN P52;

ADULT; ARTICLE; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; NUCLEAR FACTOR KAPPA B GENE; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

CASE-CONTROL STUDIES; DOWN-REGULATION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NF-KAPPA B P50 SUBUNIT; NF-KAPPA B P52 SUBUNIT; PROGNOSIS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84855449063     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9396-5     Document Type: Article

References (17)

1. Hughes C, Murphy A, Martin C et al (2005) Molecular pathology of PCA. J Clin Path 58:673-684
2. Taplin M-E, Rajeshkumar B, Halabi S et al (2003) Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21:2673-2678 (Pubitemid 46606310)
3. Beinke S, Ley SC (2004) Functions of NF-kB1 and NF-kB2 in immune cell biology. Biochem J 382:393-409 (Pubitemid 39243905)
4. Hayden MS, Ghosh S (2008) Shared principles in NF-kB signaling. Cell 132:344-362
5. Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18:2195-2224
6. Bonizzi G, Karin M (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280-288 (Pubitemid 38610351)
7. Li Q, Verma IM (2002) NF-kappa B regulation in the immune system. Nat Rev Immunol 2:725-734
8. Meylan E, Dooley AL, Feldser DM (2009) Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462:104-107
9. Xu Y, Josson S, Fang F (2009) RelB enhances prostate cancer growth: Implications for the role of the nuclear factor-KB alternative pathway in Tumorigeni City. Cancer Res 69:3267-3271
10. Lessard L, Bégin L, Gleave M et al (2005) Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: An immunohistochemical study. Br J Cancer 93:1019-1023 (Pubitemid 41548396)
11. Locke JA, Guns ES, Lubik AA (2008) Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407-6415
12. D'Antonio JM, Ma C, Monzon FA et al (2008) Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence. Prostate 68:698-714 (Pubitemid 351632942)
13. Titus MA, Schell MJ, Lih FB et al (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11:4653-4657 (Pubitemid 41557182)
14. Palvimo JJ, Reinikainen P, Ikonen T et al (1996) Mutual transcriptional interference between RelA and androgen receptor. J Biol Chem 271:24151-24156 (Pubitemid 26327398)
15. Chen CD, Sawyers CL (2002) NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 22:2862-2870 (Pubitemid 34263006)
16. Nadiminty N, Lou W, Sun M (2010) Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res 70:3309-3319
17. Nadiminty N, Chun JY, Lou Wet al (2008) NFκB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate 68:1725-1733